 |
Study Evaluates Costs and Benefits of New Chemotherapy Drugs |
| March 17th, 2010 |
| New chemotherapy agents appear associated with improvements in survival time for patients with metastatic colorectal cancer but at substantial cost. David H. Howard, PhD, and colleagues at Emory University's Rollins School of Public Health (RSPH), used a cancer registry database to measure trends in life expectancy and lifetime medical costs in 4,665 patients age 66 and older diagnosed with metastatic colon cancer between 1995 and 2005. Patients were classified according to whether they received one or more of the six chemotherapeutic agents approved for the treatment of metastatic colon cancer between 1996 and 2004.
Among those who received the new agents, life expectancy increased by 6.8 months and lifetime costs increased by $37,100, equating to a cost of $66,200 per year of life gained. After additional adjustments, the cost for each quality-adjusted life year (a year of life in perfect health) gained was $99,100, says lead study author Howard, associate professor of health policy and management, RSPH. "New chemotherapeutic agents for colorectal cancer have been singled out as examples of high-cost/low-value medical care; no doubt they are the types of therapies that would receive close scrutiny if Medicare and other payers were to consider cost-effectiveness in coverage decisions," Howard and co-authors write. "Our estimate of the cost per quality-adjusted life year gained, $100,000, is below most estimates of the willingness to pay for a life-year," the authors say. "However, continuation of Medicare's open-ended coverage policy for new chemotherapeutic agents and other expensive technologies will prove difficult to sustain as costs for the program continue to rise." The study, "The Value of New Chemotherapeutic Agents for Metastatic Colorectal Cancer," is published in the March 16, 2010 issue of the Archives of Internal Medicine, a publication of the American Medical Association. In addition to Howard, study authors were John Kauh, MD, assistant professor of hematology and medical oncology, Emory School of Medicine, and Joseph Lipscomb, PhD, professor of health policy and management, RSPH. Full Article - View Here Contact: Ashante Dobbs 404-727-5692 Emory University |
| This article is relevant to the following subject areas |
| •Medicine •Cancer •Biology |
| Copy & Share this link http://www.sciguru.com/newsitem/1974/Study-Evaluates-Costs-and-Benefits-of-New-Chemotherapy-Drugs/ |
| SciGuru.com: "Science For All". Copyright Sciguru.com © All rights reserverd (2009-present). SciGuru.com is an online source for news and information in all areas of sciences. Copy and reproduction of the contents, in full or in part, may include citation to SciGuru.com or the relevant page in SciGuru.com. |
 |
 |
 |
 |
Related NewsSmart grid could reduce emissions by 12 percentA smart electrical power grid could decrease annual electric energy use and... Nicotine Patch Improves Abstinence from Cigarettes, Helps Smokers Quit Again After RelapsePhiladelphia: New research from the University of Pennsylvania School of M... New cancer biomarker may herald personalised medicineScientists at Oxford University have led a study that shows how simple diag... Female Libido Pill Leaves Ethicist ColdCould popping a daily pill be an answer to decreased sexual desire in women... |
 |
 |
 |
Recent Science News
Novel Antiviral: LJ-double-o-one is shown to be effective against more than 20 viruses
Researchers Find New Translocation; Weak Spots in DNA Cause Genetic Disease
Beware the smell of bitter almonds. Why do many food plants contain cyanide?
Study finds structural brain alterations in patients with irritable bowel syndrome
Excellence programs do not identify safest hospitals for bariatric surgery
Asteroid Impact in 2182?
Martian Dust Devil Whirls into Opportunity's View
Study: Weight issues move up need for walkers, canes, other devices
Two Catalysts Are Better Than One
More News